Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction

J Enzyme Inhib Med Chem. 2020 Dec;35(1):629-638. doi: 10.1080/14756366.2020.1724994.

Abstract

Phialophora verrucosa causes several fungal human diseases, mainly chromoblastomycosis, which is extremely difficult to treat. Several studies have shown that human immunodeficiency virus peptidase inhibitors (HIV-PIs) are attractive candidates for antifungal therapies. This work focused on studying the action of HIV-PIs on peptidase activity secreted by P. verrucosa and their effects on fungal proliferation and macrophage interaction. We detected a peptidase activity from P. verrucosa able to cleave albumin, sensitive to pepstatin A and HIV-PIs, especially lopinavir, ritonavir and amprenavir, showing for the first time that this fungus secretes aspartic-type peptidase. Furthermore, lopinavir, ritonavir and nelfinavir reduced the fungal growth, causing remarkable ultrastructural alterations. Lopinavir and ritonavir also affected the conidia-macrophage adhesion and macrophage killing. Interestingly, P. verrucosa had its growth inhibited by ritonavir combined with either itraconazole or ketoconazole. Collectively, our results support the antifungal action of HIV-PIs and their relevance as a possible alternative therapy for fungal infections.

Keywords: Chromoblastomycosis; HIV peptidase inhibitors; antifungal activity; aspartic peptidase; cellular interaction.

MeSH terms

  • Antifungal Agents / chemical synthesis
  • Antifungal Agents / chemistry
  • Antifungal Agents / pharmacology*
  • Aspartic Acid Proteases / antagonists & inhibitors*
  • Aspartic Acid Proteases / metabolism
  • Carbamates / chemical synthesis
  • Carbamates / chemistry
  • Carbamates / pharmacology
  • Dose-Response Relationship, Drug
  • Furans
  • HIV Protease Inhibitors / chemical synthesis
  • HIV Protease Inhibitors / chemistry
  • HIV Protease Inhibitors / pharmacology*
  • Humans
  • Lopinavir / chemical synthesis
  • Lopinavir / chemistry
  • Lopinavir / pharmacology
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Microbial Sensitivity Tests
  • Molecular Structure
  • Phialophora / drug effects*
  • Phialophora / enzymology
  • Phialophora / growth & development
  • Ritonavir / chemical synthesis
  • Ritonavir / chemistry
  • Ritonavir / pharmacology
  • Structure-Activity Relationship
  • Sulfonamides / chemical synthesis
  • Sulfonamides / chemistry
  • Sulfonamides / pharmacology

Substances

  • Antifungal Agents
  • Carbamates
  • Furans
  • HIV Protease Inhibitors
  • Sulfonamides
  • Lopinavir
  • amprenavir
  • Aspartic Acid Proteases
  • Ritonavir

Grants and funding

This study was supported by grants from the Brazilian agencies: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa no Estado do Rio de Janeiro (FAPERJ), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES Financial code 001) and Fundação Oswaldo Cruz (FIOCRUZ).